StreetInsider.com News Articles

Solid Biosciences (SLDB) PT Raised to $25 at H.C. Wainwright

Wed, 03 Jun 2026 06:50:21 -0400

(Updated - June 3, 2026 6:50 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Solid Biosciences (NASDAQ: SLDB) to $25.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "Most recently, Solid Bio provided an update on its SGT-212 program for Friedreich’s ataxia (FA) along with its 1Q26 earnings report. To date, two patients have been safely dosed in the Phase 1b FALCON study, with no serious adverse events (SAEs) observed. More importantly, management noted encouraging early imaging results, with the first patient showing approximately 40% dentate coverage against a 10-20% expectation and even higher coverage in

Solid Biosciences (SLDB) PT Raised to $25 at H.C. Wainwright

Wed, 03 Jun 2026 06:50:21 -0400

(Updated - June 3, 2026 6:50 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Solid Biosciences (NASDAQ: SLDB) to $25.00 (from $20.00) while maintaining a Buy rating.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 16:05:00 -0400

This grant was made pursuant

Solid Biosciences to Participate at Upcoming Investor Conferences

Mon, 01 Jun 2026 08:00:00 -0400

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

Jefferies Global Healthcare Conference

Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for

Solid Biosciences to Participate at Upcoming Investor Conferences

Mon, 01 Jun 2026 08:00:00 -0400

Jefferies Global Healthcare Conference

Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for

Solid Biosciences (SLDB) PT Lowered to $11 at JPMorgan

Tue, 19 May 2026 07:34:14 -0400

JPMorgan analyst Anupam Rama lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $11.00 (from $12.00) while maintaining a Overweight rating.

Solid Biosciences (SLDB) PT Lowered to $16 at Wedbush

Wed, 13 May 2026 08:31:36 -0400

Wedbush analyst Laura Chico lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $16.00 (from $17.00) while maintaining a Outperform rating.

Solid Biosciences (SLDB) PT Raised to $18 at Piper Sandler

Wed, 13 May 2026 07:22:43 -0400

Piper Sandler analyst Biren Amin raised the price target on Solid Biosciences (NASDAQ: SLDB) to $18.00 (from $17.00) while maintaining a Overweight rating.

Solid Biosciences (SLDB) Misses Q1 EPS by 52c

Tue, 12 May 2026 17:09:18 -0400

Solid Biosciences (NASDAQ: SLDB) reported Q1 EPS of ($0.52).

For earnings history and earnings-related data on Solid Biosciences (SLDB) click here.

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 12 May 2026 16:08:00 -0400

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development -

- Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -

- Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON